Pure Global
NCT01642342

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

A First-In-Human Phase I Study of sEphB4-HSA in Patients With Advanced Solid Tumors With Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).
University of Southern California·Phase 1·ClinicalTrials.gov·otherTerminated
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
laboratory biomarker analysis
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
University of Southern California
Location
Los Angeles, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Sep 06, 2012
End date
May 29, 2019
Enrollment
102 participants
Primary outcome

Toxicities observed at each dose level utilizing the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0,Number of patients with complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or inevaluable (IE),Survival,Time to failure

Summary

This study is about an experimental drug called sEphB4-HSA (recombinant albumin fusion
 protein sEphB4-HSA). This research study will be the first time sEphB4-HSA is given to
 people. sEphB4-HSA prevents tumor cells from multiplying and blocks several compounds that
 promote the growth of blood vessels that bring nutrients to the tumor. sEphB4-HSA has shrunk
 colon, lung, breast, glioma, melanoma, prostate and Kaposi's sarcoma tumors in mice

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01642342
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01642342 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Southern California and is currently Terminated. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 102 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.